How should we manage a patient with a capillary glucose of 377 mg/dL who is on basal insulin glargine (Lantus) 25 U and a medium‑strength sliding‑scale insulin regimen, with a normal anion gap and normal bicarbonate?

Immediate Insulin Adjustment for Hyperglycemia with Normal Anion Gap

Increase the basal insulin (Lantus) dose by 4 units immediately and continue the medium sliding-scale insulin as a supplement—not a replacement—to the scheduled basal dose. 1

Understanding the Clinical Picture

Your patient's glucose of 377 mg/dL with a normal anion gap and bicarbonate indicates severe hyperglycemia without ketoacidosis, meaning the current basal insulin dose of 25 units is profoundly inadequate. 1 The normal anion gap rules out diabetic ketoacidosis, so this patient can be managed with aggressive subcutaneous insulin titration rather than IV insulin. 2

Why Sliding-Scale Alone Is Dangerous

The American Diabetes Association explicitly condemns sliding-scale insulin as monotherapy because it treats hyperglycemia reactively after it occurs, leading to dangerous glucose fluctuations. 2, 1, 3 Only approximately 38% of patients achieve mean glucose <140 mg/dL with sliding-scale alone, versus 68% with a scheduled basal-bolus regimen. 1 Your patient's glucose of 377 mg/dL on sliding-scale demonstrates this approach's complete failure. 1

Aggressive Basal Insulin Titration Protocol

Immediate Dose Adjustment

• Increase Lantus by 4 units every 3 days when fasting glucose remains ≥180 mg/dL, which applies to your patient with glucose of 377 mg/dL. 1
• The target fasting glucose is 80–130 mg/dL. 1
• If any glucose reading falls <70 mg/dL, reduce the basal dose by 10–20% immediately. 1

Weight-Based Dosing Expectations

• For patients with glucose 200–300 mg/dL (or higher, as in this case), typical requirements are 0.3–0.5 units/kg/day as total daily insulin. 1
• Your patient on only 25 units of Lantus is receiving approximately 0.3 units/kg/day (assuming ~80 kg body weight), which is at the lower end of what's needed for this degree of hyperglycemia. 1

Role of Sliding-Scale Insulin

Correction insulin must supplement—not replace—scheduled basal insulin. 1, 3 The medium sliding-scale should be used only for pre-meal glucose >250 mg/dL (add 2 units) or >350 mg/dL (add 4 units), in addition to the scheduled Lantus dose. 1

When to Add Prandial Insulin

• Stop escalating basal insulin when the dose approaches 0.5 units/kg/day (approximately 40 units for an 80-kg patient) without achieving targets. 1
• At that threshold, add prandial insulin (4 units before the largest meal or 10% of basal dose) rather than continuing basal escalation. 1
• Signs of "over-basalization" include: basal dose >0.5 units/kg/day, bedtime-to-morning glucose differential ≥50 mg/dL, hypoglycemia episodes, or high glucose variability. 1

Monitoring Requirements

• Check fasting glucose daily during titration to guide basal adjustments. 1
• For hospitalized patients eating regular meals, check glucose before each meal and at bedtime (minimum 4 times daily). 1, 4
• For patients with poor oral intake or NPO status, check glucose every 4–6 hours. 1, 4

Expected Clinical Outcomes

• With properly implemented basal-bolus therapy, approximately 68% of patients achieve mean glucose <140 mg/dL, compared with only 38% on sliding-scale alone. 1
• Basal insulin optimization alone can produce an HbA1c reduction of 1.5–2.0%. 1
• Properly executed regimens do not increase hypoglycemia risk relative to under-dosed insulin. 1

Critical Pitfalls to Avoid

• Do not delay basal dose escalation when glucose consistently exceeds 180 mg/dL; prolonged hyperglycemia increases complication risk. 1
• Never rely on sliding-scale insulin as monotherapy; correction doses must supplement scheduled basal insulin. 1, 3, 5
• Do not continue escalating basal insulin beyond 0.5–1.0 units/kg/day without addressing post-prandial hyperglycemia, as this leads to over-basalization and higher hypoglycemia risk. 1
• Recognize that 75% of hospitalized patients who experience hypoglycemia receive no basal insulin dose adjustment before the next dose; proactive adjustment is essential. 1

Foundation Therapy Considerations

• Continue or optimize metformin (up to 2,000 mg daily) unless contraindicated, as it reduces total insulin requirements by 20–30%. 1
• Metformin should not be discontinued during insulin intensification unless specific contraindications exist (e.g., acute infection, renal impairment, tissue hypoxia). 1, 6